Showing Results for
- Academic Journals (17)
Search Results
- 17
Academic Journals
- 17
-
From:Future Oncology (Vol. 11, Issue 1) Peer-ReviewedAuthor(s): Omar Abdel-Rahman [*] aff1 , Mona Fouad aff2 KEYWORDS everolimus; fatigue; hyperglycemia; meta-analysis Everolimus is a rapamycin derivative that inhibits the mTOR pathway by acting on mTORC1 [1 ]....
-
From:Future Oncology (Vol. 11, Issue 1) Peer-ReviewedAuthor(s): Camillo Porta [*] aff1 aff2 , Palma Giglione aff1 , Wanda Liguigli aff3 , Chiara Paglino aff1 aff2 KEYWORDS dovitinib; drug development; FGFR inhibitor; renal cell carcinoma; VEGFR inhibitor Agents...
-
From:Future Oncology (Vol. 11, Issue 1) Peer-ReviewedAuthor(s): Zachary Reese aff1 , Ali Straubhar aff2 , Sumanta K Pal aff3 , Neeraj Agarwal [*] aff1 KEYWORDS CTLA-4; immunotherapy; ipilimumab; prostate cancer Prostate cancer is the most common noncutaneous...
-
From:Future Oncology (Vol. 11, Issue 1) Peer-ReviewedAuthor(s): Anna M Czarnecka [*] aff1 , Sylwia Oborska aff2 , Piotr Rzepecki aff2 , Cezary Szczylik aff1 KEYWORDS clear cell renal cell; CML; RCC; renal cell cancer; sorafenib; sunitinib; tyrosine kinase carcinoma...
-
From:Future Oncology (Vol. 11, Issue 1) Peer-ReviewedAuthor(s): Marcello Tucci aff1 , Giorgio Vittorio Scagliotti [*] aff1 , Francesca Vignani aff1 KEYWORDS bone-targeting agents; castration-resistant prostate cancer; chemotherapy; endocrine therapy; immunotherapy...
-
From:Future Oncology (Vol. 11, Issue 1) Peer-ReviewedAuthor(s): Peter Hersey [*] aff1 , Kavitha Gowrishankar aff1 KEYWORDS 1-year survival; melanoma; PD-L1; PD1 checkpoint inhibitors; PFS; response rates The treatment of metastatic melanoma has undergone rapid...
-
From:Future Oncology (Vol. 11, Issue 1) Peer-ReviewedAuthor(s): Michael Hallek aff1 , Neil E Kay aff2 , Anders Osterborg aff3 , Asher A Chanan-Khan aff4 , Michelle Mahler aff5 , Mariya Salman aff5 , Ying Wan aff5 , Steven Sun aff5 , Sen Hong Zhuang aff5 , Angela Howes...
-
From:Future Oncology (Vol. 11, Issue 1) Peer-ReviewedAuthor(s): Diana Silva Fernandes [*] aff1 , José Manuel Lopes aff1 KEYWORDS chromosomal; epidemiology; genetic; immunohistochemical; morphology; papillary renal cell carcinoma; prognosis; treatment Epidemiology...
-
From:Future Oncology (Vol. 11, Issue 1) Peer-ReviewedAuthor(s): Francesco Perrone [*] KEYWORDS biomarkers; clinical trials; drug price; personalized medicine; precision medicine; sustainability Two important phenomena have been characterized in recent years in...
-
From:Future Oncology (Vol. 11, Issue 1) Peer-ReviewedAuthor(s): Alberto Mangano [*] aff1 , Alessandro Mangano aff2 , Georgios D Lianos aff3 , Dimitrios H Roukos aff3 , Alberto Caprioglio aff2 , Gianlorenzo Dionigi aff1 KEYWORDS head and neck squamous cell carcinoma;...
-
From:Future Oncology (Vol. 11, Issue 1) Peer-ReviewedAuthor(s): Mehmet AN Sendur [*] aff1 , Sercan Aksoy aff2 , Kadri Altundag aff2 KEYWORDS breast cancer; HER2; pertuzumab; pertuzumab-induced cardiotoxicity; trastuzumab; trastuzumab-induced cardiotoxicity...
-
From:Future Oncology (Vol. 11, Issue 1) Peer-ReviewedAuthor(s): Mao-Bin Meng [*] aff1 , Nicholas G Zaorsky aff2 , Lei Deng aff3 aff4 , Huan-Huan Wang aff1 , Jiang Chao aff1 , Lu-Jun Zhao aff1 , Zhi-Yong Yuan aff1 , Wang Ping aff1 KEYWORDS anti-angiogenesis therapy;...
-
From:Future Oncology (Vol. 11, Issue 1) Peer-ReviewedAuthor(s): Qian Huang aff1 , Xuenong Ouyang [*] aff1 aff2 aff3 aff4 KEYWORDS bone metastasis; bone metastatic microenvironment; clinical evidence; diagnostic value; miRNAs Bone is the most frequent site for...
-
From:Future Oncology (Vol. 11, Issue 1) Peer-ReviewedAuthor(s): Sebastiano Buti aff1 , Chiara Ciccarese aff2 , Daniele Zanoni aff1 , Matteo Santoni aff3 , Alessandra Modena aff2 , Francesca Maines aff2 , Annalisa Gilli aff1 , Emilio Bria aff2 , Matteo Brunelli aff4 ,...
-
From:Future Oncology (Vol. 11, Issue 1) Peer-ReviewedAuthor(s): Christian Jackisch [*] aff1 , Frank A Scappaticci aff2 , Dominik Heinzmann aff3 , Fabio Bisordi aff3 , Thomas Schreitmüller aff3 , Gunter von Minckwitz aff4 , Javier Cortés aff5 KEYWORDS biosimilar;...
-
From:Future Oncology (Vol. 11, Issue 1) Peer-ReviewedAuthor(s): Robert Pirker [*] KEYWORDS advanced lung cancer; EGFR; monoclonal antibodies; targeted therapy; tyrosine kinase inhibitors Current American Society of Clinical Oncology (ASCO) clinical guidelines for...
-
From:Future Oncology (Vol. 11, Issue 1) Peer-ReviewedAuthor(s): Ishwaria Mohan Subbiah aff1 , Vivek Subbiah [*] aff2 aff3 KEYWORDS exceptional responder; genomics; next-generation sequencing; outlier responder; unusual responder "In solving a problem of this...